About 592 patients suffering from the diseases, under the aegis of the Lysosomal Storage Disorders Society (LSDSS), have made several representations to successive governments for a corpus to take care of their treatment but in vain.
"We had made representations to several health ministers from Dinesh Trivedi to Harsh Vardhan and thought that they supported our demands, but nothing concrete has come out so far. Now we will be soon making a representation to Health Minister J P Nadda," said Manjit Singh, president of LSDSS.
"We have been asking the government to create a corpus of Rs 300 crore for the past four years to support the medication of children suffering from these disorders including Gaucher's disease. The treatment called Enzyme Replacement Therapy is very expensive and the treatment cost varies on the basis of the patient's weight.
Lysosomal Storage Diseases are a group of around 45 rare genetic disorders caused by deficiency of a specific enzyme in special compartments (lysosomes) of the cells. At present, seven of 45 LSDs are treatable whose prevalence rate ranges from 1 in 30,000 to 1 in 400,000 births.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
